Study on the treatment of acute cerebral infarction by Yinao Fujian capsule combined with fibrinolytic enzyme
Objective:To investigate the clinical effect of Ynaofujian capsule combined with fibrinolytic enzyme in the treatment of acute cerebral infarction.Methods:The clinical data of 49 patients with acute cerebral infarction treated with plasminase in our hospital from November 2019 to May 2020 were collected and included in the control group.The data of 49 patients with acute cerebral infarction treated with Ynao Fujian capsule combined with plasminase were collected and included into the observation group.Both groups were treated for 14 days.Oxidative stress indexes[(Superoxide Dismutase(SOD))and tissue-type plasminogen activator(t-PA)]were compared between the two groups before treatment and 14 days after treatment.levels,hemorheological indicators(hematocrit,fibrinogen,plasma viscosity)and adverse reactions during treatment.Results:After 14 days of treatment,SOD and t-PA levels in 2 groups were significantly higher than before treatment,and observation group was significantly higher than control group(P<0.05).The levels of hematocrit,fibrinogen and plasma viscosity in both groups were lower than before treatment,and the observation group was significantly lower than the control group(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups during treatment.Conclusion:Yinao Fujian capsule combined with fibrinolytic enzyme can improve the oxidative stress index and hemorheology in the treatment of acute cerebral infarction,and does not increase the adverse reactions.
NETL
NSTL
万方数据
维普
